Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00055523 · ClinicalTrials.gov registry record · Phase 2
A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease
A Phase 2 study of Crohn's Disease, sponsored by Abbott.
- Completed
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT00055523 is a Phase 2 study of Crohn's Disease that has completed, run by Abbott. The registered enrollment target is 300 participants, below the 2,412-participant average among 104 other Crohn's Disease trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT00055523, a Phase 2 study of Crohn's Disease, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
Purpose of the study is to test whether adalimumab can induce clinical remission in subjects with active Crohn's disease when compared to placebo (an inactive substance)
Conditions Studied
Interventions
- DRUG Adalimumab (D2E7)
Study Locations (20)
California
- Gastroenterology Associates of the East Bay - Berkeley
- Long Beach Gastroenterology Assoc. - Long Beach
- Sharp Rees-Stealy Medical Group - San Diego
Massachusetts
- Brigham and Women's Hospital - Boston
- Massachusetts General Hospital - Boston
- Clinical Pharmacology Study Group - Worcester
Florida
- Cleveland Clinic Florida - Weston
- Shafran Gastroenterology Center - Winter Park
Georgia
- Atlanta Gastroenterology Assoc. - Atlanta
- Southeastern Digestive & Liver Disease - Savannah
Illinois
- Northwest Gastroenterologists, S.C. - Arlington Heights
- University of Chicago - Chicago
Louisiana
- Drug Research Services, Inc. - Metairie
- LSU School of Medicine - New Orleans
Missouri
- Gastroenterology and Hepatology - Kansas City
- Glenn Gordon, MD - Mexico
Connecticut
- Gastroenterology Assoc. of Fairfield Co. - Bridgeport
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2002-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00055523
The ClinicalTrials.gov registry entry for NCT00055523 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,412-participant average among 104 other Crohn's Disease trials with a reported enrollment target (88% lower). The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 1 intervention - of which Adalimumab (D2E7) is the first listed.
NCT00055523 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Massachusetts, Florida.
Frequently Asked Questions
What is clinical trial NCT00055523 about?
NCT00055523 is a clinical study titled "A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease". Purpose of the study is to test whether adalimumab can induce clinical remission in subjects with active Crohn's disease when compared to placebo (an inactive substance)
What is the current status of trial NCT00055523?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2002-04.
What conditions does trial NCT00055523 study?
This clinical trial studies the following conditions: Crohn's Disease.
What interventions are being tested in trial NCT00055523?
The interventions under investigation include: Adalimumab (D2E7) (DRUG).
Who is sponsoring clinical trial NCT00055523?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00055523 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 2
-
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 2
-
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
RECRUITING · Phase 2
-
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
RECRUITING · Phase 2
-
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.